Your browser doesn't support javascript.
loading
Finger stick blood test to assess post vaccination SARS-CoV-2 neutralizing antibody response against variants
Rachel Lim; Hoi Lok Cheng; Jia Huan; Patthara Kongsuphol; Bhuvaneshwari D/O Shunmuganath; Wei Chen Ming; Say Yong Ng; Xiaohong Gao; Shuvan Prashant Turaga; Sascha P Heussler; Joyti Somani; Sharmila Sengupta; Dousabel MY Tay; Megan E McBee; Barnaby Young; Paul A MacAry; HAdley D Sikes; Peter Preiser.
Afiliação
  • Rachel Lim; Singapore-MIT Alliance in Research and Technology
  • Hoi Lok Cheng; Singapore-MIT Alliance in Research and Technology
  • Jia Huan; Singapore-MIT Alliance in Research and Technology
  • Patthara Kongsuphol; Singapore-MIT Alliance in Research and Technology
  • Bhuvaneshwari D/O Shunmuganath; National University of Singapore
  • Wei Chen Ming; Nanyang Technological University
  • Say Yong Ng; Singapore-MIT Alliance in Research and Technology
  • Xiaohong Gao; Nanyang Technological University
  • Shuvan Prashant Turaga; Attonics System Pte
  • Sascha P Heussler; Attonics System Pte
  • Joyti Somani; National University Hospital
  • Sharmila Sengupta; National University Hospital
  • Dousabel MY Tay; MIT
  • Megan E McBee; Singapore-MIT Alliance in Research and Technology
  • Barnaby Young; National Centre for Infectious Diseases
  • Paul A MacAry; National University of Singapore
  • HAdley D Sikes; Singapore-MIT Alliance in Research and Technology
  • Peter Preiser; Nanyang Technological University
Preprint em En | PREPRINT-MEDRXIV | ID: ppmedrxiv-21266241
ABSTRACT
There is clinical need for a quantifiable point-of-care (PoC) SARS-CoV-2 neutralizing antibody (nAb) test that is adaptable with the pandemics changing landscape. Here, we present a rapid and semi-quantitative nAb test that uses finger stick or venous blood to assess the nAb response of vaccinated population against wild-type, alpha, beta, gamma, and delta variant receptor binding domains. It captures a clinically relevant range of nAb levels, and effectively differentiates pre-vaccination, post 1st dose and post 2nd dose vaccination samples within 10 minutes. The data observed against alpha, beta, gamma, and delta variants agrees with published results evaluated in established serology tests. Finally, our test revealed a substantial reduction in nAb level for beta, gamma, and delta variants between early BNT162b2 vaccination group (within 3 months) and later vaccination group (post 3 months). This test is highly suited for PoC settings and provides an insightful nAb response in a post-vaccinated population.
Licença
cc_no
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Experimental_studies / Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Experimental_studies / Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Preprint